Glenn Larsen
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2015First federal award
$19.6MFederal grants as PI15 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
15 awards · $19.6M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Sep 2, 2026 | NIH | SBIR Phase II Development of a novel oral brain penetrant therapeutic for ALS disease | $1.5M | Aquinnah Pharmaceuticals Inc. |
| Aug 26, 2026 | NIH | SBIR Phase II Development of a novel Alzheimer's disease therapeutic targeting tau | $998K | Aquinnah Pharmaceuticals Inc. |
| Jul 16, 2025 | NIH | SBIR Phase II Development of a novel Alzheimer's disease therapeutic targeting tau | $999K | Aquinnah Pharmaceuticals Inc. |
| Jun 13, 2025 | NIH | SBIR Phase II Development of a novel oral brain penetrant therapeutic for ALS disease | $1.5M | Aquinnah Pharmaceuticals Inc. |
| Sep 12, 2024 | NIH | SBIR Phase II Development of a novel Alzheimer's disease therapeutic targeting tau | $1000K | Aquinnah Pharmaceuticals Inc. |
| May 27, 2021 | NIH | SBIR Phase II Targeting tau for the development of novel Alzheimer's disease therapeutics | $1.0M | Aquinnah Pharmaceuticals Inc. |
| May 1, 2020 | NIH | SBIR Phase II Targeting tau for the development of novel Alzheimer's disease therapeutics | $2.5M | Aquinnah Pharmaceuticals Inc. |
| Apr 23, 2020 | NIH | SBIR Phase II Targeting tau for the development of novel Alzheimer's disease therapeutics | $1.5M | Aquinnah Pharmaceuticals Inc. |
| Aug 5, 2019 | NIH | SBIR Phase II TDP-43 aggregation inhibitors for the treatment of ALS | $2.5M | Aquinnah Pharmaceuticals Inc. |
| Sep 7, 2018 | NIH | SBIR Phase I Tau/TIA1 aggregation inhibitors for the treatment of AD | $379K | Aquinnah Pharmaceuticals Inc. |
| May 15, 2018 | NIH | SBIR Phase II TDP-43 aggregation inhibitors for the treatment of ALS | $3.4M | Aquinnah Pharmaceuticals Inc. |
| May 7, 2018 | NIH | SBIR Phase II TDP-43 aggregation inhibitors for the treatment of ALS | $924K | Aquinnah Pharmaceuticals Inc. |
| Sep 19, 2016 | NIH | SBIR Phase I TDP-43 aggregation inhibitors for the treatment of ALS | $183K | Aquinnah Pharmaceuticals Inc. |
| Sep 15, 2015 | NIH | SBIR Phase I TDP-43 aggregation inhibitors for the treatment of ALS | $682K | Aquinnah Pharmaceuticals Inc. |
| Sep 14, 2015 | NIH | SBIR Phase I TDP-43 aggregation inhibitors for the treatment of ALS | $500K | Aquinnah Pharmaceuticals Inc. |
Peer ranks
Federal funding#6
Awards as PI#46
Patents#273
Companies
- Aquinnah Pharmaceuticals Inc.Linked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.